Le Lézard
Classified in: Health, Science and technology, Business
Subject: SHAREHOLDER RIGHTS PLANS

Spectral Medical Inc. Announces Closing of Approximately C$8.5 Million Convertible Notes Financing


NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA.

TORONTO, May 30, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (TSX:EDT) (the "Company" or "Spectral"), is pleased to confirm the closing of previously announced offering of 9% convertible notes of the Company at a price of US$1,000 per convertible note due on May 1, 2028 for gross proceeds of approximately C$8.5 million (the "Offering"). Paradigm Capital Inc. acted as the underwriter for the Offering. The net proceeds from the Offering are expected to be primarily used by the Company on its Phase III registration trial (Tigris) for its PMX treatment for endotoxemic septic shock and for general corporate and working capital purposes.

The securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any U.S. state securities laws, and may not be offered or sold in the United States without registration under the U.S. Securities Act and all applicable state securities laws or compliance with the requirements of an applicable exemption therefrom. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor may there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About SPECTRAL MEDICAL INC.

Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxintm ("PMX"). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's Endotoxin Activity Assay (EAAtm), the only FDA cleared diagnostic for the risk of developing sepsis.

PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. In July 2022, the U.S. FDA granted Breakthrough Device Designation for PMX for the treatment of endotoxic septic shock. Approximately 330,000 patients are diagnosed with septic shock in North America each year.

The Tigris Trial is a confirmatory study of PMX in addition to standard care vs standard care alone and is designed as a 2:1 randomized trial of 150 patients using Bayesian statistics. Endotoxic septic shock is a malignant form of sepsis https://www.youtube.com/watch?v=6RANrHHi9L8.

The trial methods are detailed in "Bayesian methods: a potential path forward for sepsis trials".

Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit www.spectraldx.com.

Forward-looking Information Cautionary Statement

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

For further information, please contact:

Ali MahdaviChris Seto
Capital Markets & Investor RelationsCEO
Spinnaker Capital Markets Inc.Spectral Medical Inc.
416-962-3300 
[email protected][email protected]


These press releases may also interest you

at 07:35
Element Solutions Inc ("Element Solutions") announced today that it intends to release its 2024 third quarter financial results after the market close on Monday, October 28th, 2024. Element Solutions will host a webcast/dial-in conference call to...

at 07:35
You are invited to join the senior management of Arcos Dorados Holdings Inc. on a webcast to discuss the Company's results for the third quarter ended September 30, 2024, which will be released before the market opens on Wednesday, November 13,...

at 07:35
nLIGHT, Inc. announced that it will release its financial results for the third quarter of 2024 after the financial markets close on Thursday, November 7, 2024. A conference call and simultaneous webcast to discuss the third quarter results will be...

at 07:35
Aramark , a global leader in food and facilities management, announced that it will host a conference call to review its fourth quarter and full year fiscal 2024 results on Monday, November 11, 2024 at 8:30 a.m. ET. A news release containing the...

at 07:30
Recent Zillow® research shows Hispanic homeowners making strides in narrowing the home value gap with white homeowners over the past two years, regaining ground lost during the pandemic. The gap is now the narrowest ever observed....

at 07:05
SolarEdge Technologies, Inc. ("SolarEdge") , a global leader in smart energy technology, will report financial results for the third quarter ended September 30, 2024 after market close on Wednesday, November 6, 2024. Management will host a conference...



News published on and distributed by: